Randomized Controlled Clinical Trial of Weight Loss Programs in Obese Persons (SHINE)
Primary Purpose
Obesity
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
SHINE
Sponsored by

About this trial
This is an interventional treatment trial for Obesity focused on measuring obesity, randomized controlled trial, weight loss, metabolic syndrome
Eligibility Criteria
Inclusion Criteria:
- Age 18+ years old
- BMI > 30-45
- Waist circumference > 102 cm (men) or > 88 cm (women)
- Live in San Francisco Bay Area and able to attend more than 16 classes and up to 12 assessment visits in San Francisco over an 18 month period
Exclusion Criteria:
- Inability to provide informed consent
- Age < 18
- A substance abuse, mental health, or medical condition that, in the opinion of investigators, will make it difficult for the potential participant to participate in the group intervention
- Type I or II Diabetes or fasting glucose ≥ 126 mg/dl or hemoglobin A1c ≥ 6.5; those with HbA1c between 6-6.5% may complete an OGTT to rule out diabetes (glucose <200 mg/dl)
- Use of systemic (oral or IV) corticosteroids in the 6 months prior to enrollment or severe autoimmune disorders or other conditions (e.g. rheumatoid arthritis, lupus), that are likely to require these medications
- Use of immunosuppressive or immunomodulating drugs or chronic or acute conditions that would require the use of such medications
- A history of known coronary artery disease (CAD), or typical or atypical anginal chest pain requires a letter from the participant's physician that he or she has been adequately evaluated and that a moderate exercise program is appropriate
- Non English speaker
- Pregnant or planning to get pregnant in the next 12 months, breastfeeding or less than 6 months post-partum
- Initiation of new class of psychiatric medications in past 2 months
- Currently on a specific weight loss diet
- For influenza vaccine administration: a prior allergic reaction to the influenza vaccine or eggs. These participants can be included in the trial but will be excluded from participation in influenza vaccination.
- Active bulimia or strong history of bulimia
- Current use of weight loss medications or supplements such as amphetamine-based drugs that are believed to have some effect on weight
- History of or planned weight loss surgery
- Untreated hypothyroidism: TSH > 4mU/mL (or the upper limit of normal reference defined by the lab doing the assay)
Sites / Locations
- Osher Center for Integrative Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
SHINE A
SHINE B
Arm Description
Outcomes
Primary Outcome Measures
weight loss and maintenance of weight loss
Secondary Outcome Measures
fat distribution
insulin sensitivity
perceived stress
mood
stress hormones
autonomic nervous system function
adipocyte activity
influenza vaccine response
Full Information
NCT ID
NCT00960414
First Posted
August 13, 2009
Last Updated
May 5, 2014
Sponsor
University of California, San Francisco
Collaborators
National Center for Complementary and Integrative Health (NCCIH)
1. Study Identification
Unique Protocol Identification Number
NCT00960414
Brief Title
Randomized Controlled Clinical Trial of Weight Loss Programs in Obese Persons
Acronym
SHINE
Official Title
Supporting Health by Integrating Nutrition and Exercise (SHINE)
Study Type
Interventional
2. Study Status
Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
August 2009 (undefined)
Primary Completion Date
August 2013 (Actual)
Study Completion Date
August 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
Collaborators
National Center for Complementary and Integrative Health (NCCIH)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to compare two approaches to a diet and exercise-based weight loss program.
Detailed Description
The high prevalence of obesity and its medical consequences make it one of the most important public health issues in the United States today. Few interventions have been consistently successful at reducing obesity. This trial will test an intervention program that lasts 22 weeks, with 16 evening sessions and one weekend day. Participants will be randomized to one of two arms. Both arms will receive diet and exercise intervention elements. The study aims for gradual weight loss, with a calorie target that will maintain ideal body weight, rather than a more calorie restricted diet. The exercise component is based around increasing walking. The arms will compare methods for producing long-lasting behavior change.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
obesity, randomized controlled trial, weight loss, metabolic syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
194 (Actual)
8. Arms, Groups, and Interventions
Arm Title
SHINE A
Arm Type
Experimental
Arm Title
SHINE B
Arm Type
Active Comparator
Intervention Type
Behavioral
Intervention Name(s)
SHINE
Intervention Description
Both groups will receive a diet and exercise based intervention aimed at eating a caloric intake that will maintain ideal body weight and increasing exercise. SHINE A will emphasize awareness of hunger and satiety cues, while SHINE B will receive more detained nutritional education.
Primary Outcome Measure Information:
Title
weight loss and maintenance of weight loss
Time Frame
0,3,6,12,18 months
Secondary Outcome Measure Information:
Title
fat distribution
Time Frame
0, 6 mo
Title
insulin sensitivity
Time Frame
0, 3,6,12,18 mo
Title
perceived stress
Time Frame
0, 3,6,12,18 mo
Title
mood
Time Frame
0, 3,6,12,18 mo
Title
stress hormones
Time Frame
0, 6, 12 mo
Title
autonomic nervous system function
Time Frame
0, 3,6,12
Title
adipocyte activity
Time Frame
0, 6 mo
Title
influenza vaccine response
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age 18+ years old
BMI > 30-45
Waist circumference > 102 cm (men) or > 88 cm (women)
Live in San Francisco Bay Area and able to attend more than 16 classes and up to 12 assessment visits in San Francisco over an 18 month period
Exclusion Criteria:
Inability to provide informed consent
Age < 18
A substance abuse, mental health, or medical condition that, in the opinion of investigators, will make it difficult for the potential participant to participate in the group intervention
Type I or II Diabetes or fasting glucose ≥ 126 mg/dl or hemoglobin A1c ≥ 6.5; those with HbA1c between 6-6.5% may complete an OGTT to rule out diabetes (glucose <200 mg/dl)
Use of systemic (oral or IV) corticosteroids in the 6 months prior to enrollment or severe autoimmune disorders or other conditions (e.g. rheumatoid arthritis, lupus), that are likely to require these medications
Use of immunosuppressive or immunomodulating drugs or chronic or acute conditions that would require the use of such medications
A history of known coronary artery disease (CAD), or typical or atypical anginal chest pain requires a letter from the participant's physician that he or she has been adequately evaluated and that a moderate exercise program is appropriate
Non English speaker
Pregnant or planning to get pregnant in the next 12 months, breastfeeding or less than 6 months post-partum
Initiation of new class of psychiatric medications in past 2 months
Currently on a specific weight loss diet
For influenza vaccine administration: a prior allergic reaction to the influenza vaccine or eggs. These participants can be included in the trial but will be excluded from participation in influenza vaccination.
Active bulimia or strong history of bulimia
Current use of weight loss medications or supplements such as amphetamine-based drugs that are believed to have some effect on weight
History of or planned weight loss surgery
Untreated hypothyroidism: TSH > 4mU/mL (or the upper limit of normal reference defined by the lab doing the assay)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Frederick Hecht, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Elissa Epel, PhD
Organizational Affiliation
University of California, San Francisco
Official's Role
Study Chair
Facility Information:
Facility Name
Osher Center for Integrative Medicine
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
34544560
Citation
Jake-Schoffman DE, Brown SD, Baiocchi M, Bibeau JL, Daubenmier J, Ferrara A, Galarce MN, Hartogensis W, Hecht FM, Hedderson MM, Moran PJ, Pagoto SL, Tsai AL, Waring ME, Kiernan M. Methods-Motivational Interviewing Approach for Enhanced Retention and Attendance. Am J Prev Med. 2021 Oct;61(4):606-617. doi: 10.1016/j.amepre.2021.04.005.
Results Reference
derived
PubMed Identifier
33214537
Citation
Daubenmier J, Chao MT, Hartogensis W, Liu R, Moran PJ, Acree MC, Kristeller J, Epel ES, Hecht FM. Exploratory Analysis of Racial/Ethnic and Educational Differences in a Randomized Controlled Trial of a Mindfulness-Based Weight Loss Intervention. Psychosom Med. 2021 Jul-Aug 01;83(6):503-514. doi: 10.1097/PSY.0000000000000859.
Results Reference
derived
PubMed Identifier
31724424
Citation
Radin RM, Epel ES, Daubenmier J, Moran P, Schleicher S, Kristeller J, Hecht FM, Mason AE. Do stress eating or compulsive eating influence metabolic health in a mindfulness-based weight loss intervention? Health Psychol. 2020 Feb;39(2):147-158. doi: 10.1037/hea0000807. Epub 2019 Nov 14.
Results Reference
derived
PubMed Identifier
29901486
Citation
Mason AE, Hecht FM, Daubenmier JJ, Sbarra DA, Lin J, Moran PJ, Schleicher SG, Acree M, Prather AA, Epel ES. Weight Loss Maintenance and Cellular Aging in the Supporting Health Through Nutrition and Exercise Study. Psychosom Med. 2018 Sep;80(7):609-619. doi: 10.1097/PSY.0000000000000616.
Results Reference
derived
PubMed Identifier
29842903
Citation
Hecht FM, Moskowitz JT, Moran P, Epel ES, Bacchetti P, Acree M, Kemeny ME, Mendes WB, Duncan LG, Weng H, Levy JA, Deeks SG, Folkman S. A randomized, controlled trial of mindfulness-based stress reduction in HIV infection. Brain Behav Immun. 2018 Oct;73:331-339. doi: 10.1016/j.bbi.2018.05.017. Epub 2018 May 26.
Results Reference
derived
PubMed Identifier
26955895
Citation
Daubenmier J, Moran PJ, Kristeller J, Acree M, Bacchetti P, Kemeny ME, Dallman M, Lustig RH, Grunfeld C, Nixon DF, Milush JM, Goldman V, Laraia B, Laugero KD, Woodhouse L, Epel ES, Hecht FM. Effects of a mindfulness-based weight loss intervention in adults with obesity: A randomized clinical trial. Obesity (Silver Spring). 2016 Apr;24(4):794-804. doi: 10.1002/oby.21396. Epub 2016 Mar 9.
Results Reference
derived
PubMed Identifier
26867697
Citation
Mason AE, Epel ES, Aschbacher K, Lustig RH, Acree M, Kristeller J, Cohn M, Dallman M, Moran PJ, Bacchetti P, Laraia B, Hecht FM, Daubenmier J. Reduced reward-driven eating accounts for the impact of a mindfulness-based diet and exercise intervention on weight loss: Data from the SHINE randomized controlled trial. Appetite. 2016 May 1;100:86-93. doi: 10.1016/j.appet.2016.02.009. Epub 2016 Feb 8.
Results Reference
derived
Links:
URL
http://www.osher.ucsf.edu/research/enroll-in-research-studie/shine-study/
Description
The SHINE Study: Supporting Health by Integrating Nutrition and Exercise
Learn more about this trial
Randomized Controlled Clinical Trial of Weight Loss Programs in Obese Persons
We'll reach out to this number within 24 hrs